-
Colesevelam is a bile-sequestering agent approved in 2000 for the treatment of hypercholesterolemia. It has recently been shown to be effective as add-on therapy for Type 2 diabetics.
-
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
-
Women who had low serum 25(OH) vitamin D concentrations were observed to have a higher hip fracture risk independent of other factors.
-
Topical agents, both as monotherapy and in combination, have shown efficacy in management of acne. Benzoyl peroxide (BPO) is one of the most commonly used agents, but despite excellent efficacy, the side effects of skin dryness, burning, erythema, and peeling are sometimes limiting effects of treatment.
-
The ECG shown was obtained from a 60-year-old man who was seen in the office. How would you interpret this tracing if you did not have more information? Is there cause for potential concern?
-
Inhaled salmeterol and fluticasone, singly or in combination, reduce the rate of decline of the FEV1 in patients with moderate-to-severe COPD.
-
CT colonographic screening of asymptomatic adults identified 90% of polyps or cancers measuring 10 mm or more.
-
Homocysteine (HCYS) has all the trappings of a first-rate cardiovascular risk factor: as strong an association with CVD endpoints as cholesterol, ease of identification, and simplicity of modulation. Trouble is, trials to date have been unable to show that reductions of homocysteine provide meaningful benefits to patients.
-
Intensive hemoglobin A1c lowering does not reduce the rate of cardiovascular death, and results in an increase in hypoglycemic events.
-
